RxDoctor Payments Data

Dolores King, MD

Internal Medicine · Fort Worth, TXNPI 1780619486

Payments from drug & device makers

$7,851in general payments, 2019–2025

Across 491 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • AstraZeneca$662
  • Boehringer Ingelheim$547
  • Pfizer$427
  • plus $3K from 39 others

What the payments were for

  • Speaking & faculty fees$1502%
  • Food & beverage$7,66898%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,851 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$53,274
Medicare patients
182
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide182$224,581
MounjaroTirzepatide132$147,028
EliquisApixaban77$86,696
Egrifta SvTesamorelin Acetate12$85,754
JardianceEmpagliflozin45$60,957
LinzessLinaclotide51$48,100
TrulicityDulaglutide23$44,438
JanuviaSitagliptin Phosphate26$31,695
FarxigaDapagliflozin Propanediol29$29,934
Tresiba Flextouch U-200Insulin Degludec27$27,206
RybelsusSemaglutide13$26,190
XareltoRivaroxaban15$23,616
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$19,021
Breo ElliptaFluticasone/Vilanterol23$14,761
TradjentaLinagliptin15$14,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,269$250,771195 claims
Lilly USA, LLCMounjaro, Trulicity$1,103$191,467155 claims
PfizerEliquis$427$86,69677 claims
Boehringer IngelheimJardiance, Tradjenta$547$74,95760 claims
AbbVieLinzess, Restasis, Synthroid$1,052$63,295103 claims
AstraZenecaFarxiga, Symbicort$662$33,91541 claims
MerckJanuvia$48$31,69526 claims
Johnson & JohnsonXarelto$53$23,61615 claims
GSKBreo Ellipta$206$14,76123 claims
BayerKerendia$350$12,86611 claims
Idorsia Pharmaceuticals US IncQuviviq$63$8,56417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →